Abstract 385P
Background
Introduction: Breast Cancer is one of the most common cancer in Iranian women. Whole genome association study of breast cancer have recognized various single nucleotide polymorphisms (SNPs) that are related with increased breast cancer risk in the population. This study aimed at assessing the correlation between caspase-8 (CASP8) gene polymorphisms (rs3754934 and rs12990906) and the pathogenesis of breast cancer in Northeast of Iran.
Methods
In a case- control study a total of 450 breast cancer cases and 553 healthy subjects were included in this study. Polymorphisms were genotyped by amplification-refractory mutation system (ARMS). The chi-squared test was used to calculate Odds ratio (OR) with 95% confidence interval to determine the relationship between CASP8 polymorphisms and breast cancer risk.
Results
According to the results, after adjustment for confounding factors, rs3754934 in dominant model (CA+AA vs. CC) [p = 0.004, OR = 0.49 95% CI (0.27-0.78)] and rs12990906 in allelic model (T vs. C) [p = 0.026, OR = 1.27, 95%CI (1.03-1.58)] were associated with the risk of breast cancer in this population. We did not find any association with breast cancer risk factors, clinical and pathologic features and prognosis and considered polymorphisms.
Conclusions
Polymorphisms of CASP8 gene may have a crucial role in association with the risk of breast cancer. However, further larger studies can confirm such findings. An understanding of the mode of action of these variants will aid individual-level breast cancer risk prediction.
Clinical trial identification
Editorial acknowledgement
The authors thank all participants in this research. We would also like to thank Mashhad University of Medical Sciences and Omid hospital to support the project.
Legal entity responsible for the study
Mashhad University of Medical Sciences.
Funding
Mashhad University of Medical Sciences.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
465P - A phase IIIb open-label study of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC: Exploratory biomarker analysis
Presenter: Jie Wang
Session: Poster display session
Resources:
Abstract
470P - Prognostic significance of serum biomarkers in small cell lung cancer: A meta-analysis and systematic review
Presenter: Rogelio Velasco
Session: Poster display session
Resources:
Abstract
471P - Chemotherapy in advanced thymic malignancies
Presenter: Ankur Varshney
Session: Poster display session
Resources:
Abstract
466P - Cancer immunotherapy efficacy and patients’ age: A systematic review and meta-analysis
Presenter: Yu Jiang
Session: Poster display session
Resources:
Abstract
506P - Efficacy and safety of pegvorhyaluronidase alfa (PEGPH20; PVHA) and pembrolizumab (pembro) combination therapy in patients (Pts) with stage III/IV non-small cell lung cancer (NSCLC)
Presenter: Jeffrey Ward
Session: Poster display session
Resources:
Abstract
480P - Safety and efficacy of dacomitinib for EGFR+ NSCLC in the subgroup of Asian patients from ARCHER 1050
Presenter: Tony S.K. Mok
Session: Poster display session
Resources:
Abstract
503P - Activity of afatinib in patients (pts) with NSCLC harboring uncommon EGFR mutations: Pooled analysis of three large phase IIIB trials
Presenter: Antonio Passaro
Session: Poster display session
Resources:
Abstract
488P - Randomized trial of prophylactic minocycline for erlotinib-associated skin rash in non-small cell lung cancer (PEARL trial)
Presenter: Kei Kusaka
Session: Poster display session
Resources:
Abstract
495P - Tracking of activating EGFR mutations predicts progression-free survival in advanced EGFR-mutated NSCLC patients treated with osimertinib
Presenter: Anna Buder
Session: Poster display session
Resources:
Abstract
520P - A phase II study to evaluate abscopal effect by palliative radiation therapy in nivolumab treatment for pretreated non-small cell lung cancer (HANSHIN 0116)
Presenter: Akito Hata
Session: Poster display session
Resources:
Abstract